Ainos, Inc. (AIMD)
After hours:
| Previous close | 0.6050 |
| Open | 0.6545 |
| Bid | 0.6050 x 800 |
| Ask | 0.6200 x 2200 |
| Day's range | 0.6049 - 0.6989 |
| 52-week range | 0.5540 - 1.9100 |
| Volume | |
| Avg. volume | 254,261 |
| Market cap | 12.581M |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8200 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAinos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals
Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has published preclinical data demonstrating the potential of its low-dose oral interferon-alpha (IFNα) formulation, VELDONA®, as treatment candidates for the two most common medical conditions for dogs and cats. The preclinical data can be a
PR NewswireAinos Reports Unaudited Third Quarter 2022 Financial Results
Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the third quarter ended September 30, 2022.
PR NewswireFive New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha ("IFNα") formulation, VELDONA®. Ainos has completed Phase 2 trials for the five new drug candidates and will work with potential partn
